187 related articles for article (PubMed ID: 22042416)
1. [Inflammatory bowel disease and lymphoproliferative disorders].
Ye BD
Korean J Gastroenterol; 2011 Oct; 58(4):171-7. PubMed ID: 22042416
[TBL] [Abstract][Full Text] [Related]
2. Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders with a T- or NK-cell phenotype.
Satou A; Tsuzuki T; Nakamura S
J Clin Exp Hematop; 2019; 59(2):56-63. PubMed ID: 31257346
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle.
Sokol H; Beaugerie L
Gut; 2009 Oct; 58(10):1427-36. PubMed ID: 19749141
[TBL] [Abstract][Full Text] [Related]
4. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.
Subramaniam K; D'Rozario J; Pavli P
J Gastroenterol Hepatol; 2013 Jan; 28(1):24-30. PubMed ID: 23094824
[TBL] [Abstract][Full Text] [Related]
5. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
6. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
7. [Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease].
Kim JH; Kim JW
Korean J Gastroenterol; 2017 Oct; 70(4):162-168. PubMed ID: 29060953
[TBL] [Abstract][Full Text] [Related]
8. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
9. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?
Jones JL; Loftus EV
Inflamm Bowel Dis; 2007 Oct; 13(10):1299-307. PubMed ID: 17600819
[TBL] [Abstract][Full Text] [Related]
10. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).
Magro F; Peyrin-Biroulet L; Sokol H; Aldeger X; Costa A; Higgins PD; Joyce JC; Katsanos KH; Lopez A; de Xaxars TM; Toader E; Beaugerie L
J Crohns Colitis; 2014 Jan; 8(1):31-44. PubMed ID: 23721759
[TBL] [Abstract][Full Text] [Related]
11. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
12. Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study.
Mamtani R; Clark AS; Scott FI; Brensinger CM; Boursi B; Chen L; Xie F; Yun H; Osterman MT; Curtis JR; Lewis JD
Arthritis Rheumatol; 2016 Oct; 68(10):2403-11. PubMed ID: 27159030
[TBL] [Abstract][Full Text] [Related]
13. Monitoring for Extra-Intestinal Cancers in IBD.
Sifuentes H; Kane S
Curr Gastroenterol Rep; 2015 Nov; 17(11):42. PubMed ID: 26364836
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.
Kotlyar DS; Osterman MT; Diamond RH; Porter D; Blonski WC; Wasik M; Sampat S; Mendizabal M; Lin MV; Lichtenstein GR
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):36-41.e1. PubMed ID: 20888436
[TBL] [Abstract][Full Text] [Related]
15. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
[TBL] [Abstract][Full Text] [Related]
16. Hepatosplenic T-cell lymphoma and inflammatory bowel disease.
Thai A; Prindiville T
J Crohns Colitis; 2010 Nov; 4(5):511-22. PubMed ID: 21122554
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD.
Dulai PS; Siegel CA; Peyrin-Biroulet L
Gastroenterol Clin North Am; 2014 Sep; 43(3):441-56. PubMed ID: 25110252
[TBL] [Abstract][Full Text] [Related]
18. Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy.
Ramos JM; García-Sepulcre MF; Masiá M; Brotons A; Grau MC; Gutiérrez F
Rev Esp Enferm Dig; 2010 Oct; 102(10):614-6. PubMed ID: 21039077
[No Abstract] [Full Text] [Related]
19. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
[TBL] [Abstract][Full Text] [Related]
20. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment.
Aithal GP; Mansfield JC
Aliment Pharmacol Ther; 2001 Aug; 15(8):1101-8. PubMed ID: 11472312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
